Mogamulizumab
| Mogamulizumab | |
|---|---|
| Term | Mogamulizumab |
| Short definition | Mogamulizumab - (pronounced) (moh-GAM-yoo-LIH-zoo-mab) medicine used to treat adults with mycosis fungoides or Sezary syndrome (types of cutaneous T-cell lymphoma) that have come back or have not improved after treatment with at least one systemic therapy. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Mogamulizumab - (pronounced) (moh-GAM-yoo-LIH-zoo-mab) medicine used to treat adults with mycosis fungoides or Sezary syndrome (types of cutaneous T-cell lymphoma) that have come back or have not improved after treatment with at least one systemic therapy. It is also being studied in the treatment of other types of cancer. Mogamulizumab attaches to a protein called CCR4, which is found on some T cells (a type of white blood cell) and some types of lymphoma cells. Mogamulizumab can block this protein and help the immune system kill cancer cells. It's a type of monoclonal antibody. Also called Poteligeo
External links
- Medical encyclopedia article on Mogamulizumab
- Wikipedia's article - Mogamulizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski